BPC-157 + TB-500 Stack: The Complete Repair Protocol Guide
Last updated: April 14, 2026 · 12 min read · Reviewed by Grey Peptides Editorial Board
TL;DR
The BPC-157 + TB-500 stack is the most widely used peptide combination for tissue repair. It works because the two peptides heal through completely different mechanisms — BPC-157 builds new blood vessels to supply the injury site (angiogenesis), while TB-500 mobilizes repair cells to migrate to damaged areas (cell migration) and reduces inflammation. Together, you get both the infrastructure and the workforce that healing requires. The standard protocol runs 8 weeks: BPC-157 at 500 mcg twice daily near the injury, TB-500 at 2.5 mg twice weekly for weeks 1–4 (loading), then 1.5 mg once weekly for weeks 5–8 (maintenance).
→ This stack is rated "Strong Synergy" in our Interaction Checker.
→ Calculate exact dosages for both peptides with our Reconstitution Calculator.
Table of Contents
- Why This Stack Works
- The Synergy Explained
- Complete Protocol (3 Tiers)
- Week-by-Week Dosing Schedule
- Reconstitution & Preparation
- Injection Strategy
- What to Expect (Timeline)
- Cost Breakdown
- Adding a Third Peptide
- Troubleshooting Common Issues
- Frequently Asked Questions
- Sources
Why This Stack Works
Every tissue repair process in the body requires two fundamental things: a blood supply to deliver nutrients, oxygen, and growth factors to the damage site, and repair cells that migrate to the area to rebuild the damaged structure.
BPC-157 and TB-500 each address one of these requirements through independent biological pathways. This is not redundancy — it's genuine synergy. Each peptide does something the other cannot.
BPC-157 builds the infrastructure. Through VEGF upregulation, it promotes angiogenesis — the formation of new blood vessels from existing vasculature. It also modulates the nitric oxide system and enhances growth hormone receptor expression in connective tissue cells. Its effects are most potent locally, which is why it's injected near the injury site.
TB-500 mobilizes the workforce. Through G-actin binding, it promotes cell migration — the physical movement of fibroblasts, endothelial cells, and immune cells toward the injury. It also reduces inflammation (which can impede repair) and supports tissue remodeling. Its effects are systemic, working body-wide regardless of injection location.
When combined, you get accelerated blood vessel formation delivering nutrients to the repair site AND enhanced cell migration bringing repair machinery to the same location AND reduced inflammatory barriers to healing AND improved growth hormone receptor sensitivity. No single peptide achieves all four.
→ For a detailed mechanism comparison, see our article: BPC-157 vs TB-500.
The Synergy Explained
The word "synergy" gets overused in the peptide space, but the BPC-157 + TB-500 combination genuinely qualifies. Here's why.
Complementary, not overlapping. The two peptides activate entirely different biological pathways. BPC-157's primary mechanism (VEGF/angiogenesis) and TB-500's primary mechanism (actin regulation/cell migration) do not compete for the same receptors or signaling molecules. They operate in parallel, each amplifying a different component of the repair process.
Temporal synergy. BPC-157's shorter half-life (~4 hours) with twice-daily dosing creates consistent local repair signaling throughout the day. TB-500's longer half-life (~24 hours) with twice-weekly dosing builds a sustained systemic recovery environment. The different dosing rhythms mean there's always active repair signaling in the body from one or both compounds.
Tissue coverage. BPC-157 injected near the injury creates a concentrated repair zone with enhanced blood supply. TB-500 injected systemically ensures repair cells from throughout the body are mobilized toward injury sites. Together, you address both the local and systemic components of tissue healing.
This is why the BPC-157 + TB-500 stack isn't just "two repair peptides" — it's two fundamentally different repair strategies working simultaneously.
Complete Protocol (3 Tiers)
Beginner Protocol (Single Peptide Start)
If you've never used peptides before, start with BPC-157 alone for the first 2 weeks before adding TB-500. This lets you assess your response to one compound before introducing a second.
| Peptide | Weeks | Dose | Frequency | Route |
|---|---|---|---|---|
| BPC-157 | 1–2 | 250 mcg | 1x daily | SubQ near injury |
| BPC-157 | 3–8 | 500 mcg | 2x daily | SubQ near injury |
| TB-500 | 3–6 | 2.5 mg | 2x/week | SubQ (any site) |
| TB-500 | 7–8 | 1.5 mg | 1x/week | SubQ (any site) |
Total duration: 8 weeks Injections per week: Weeks 1–2: 7 (BPC only). Weeks 3–6: 16 (BPC 2x/day + TB 2x/week). Weeks 7–8: 15 (BPC 2x/day + TB 1x/week).
Intermediate Protocol (Standard Stack)
The most commonly used version. Both peptides start simultaneously.
| Peptide | Phase | Weeks | Dose | Frequency | Route |
|---|---|---|---|---|---|
| BPC-157 | Continuous | 1–8 | 500 mcg | 2x daily (AM + PM) | SubQ near injury |
| TB-500 | Loading | 1–4 | 2.5 mg | 2x/week | SubQ (any site) |
| TB-500 | Maintenance | 5–8 | 1.5 mg | 1x/week | SubQ (any site) |
Total duration: 8 weeks Key timing: BPC-157 morning and evening. TB-500 on any two non-consecutive days during loading (e.g., Monday/Thursday).
Advanced Protocol (Extended + GH Support)
For significant injuries or athletes with high training loads. Adds GH secretagogues to create an enhanced recovery environment.
| Peptide | Phase | Weeks | Dose | Frequency | Route |
|---|---|---|---|---|---|
| BPC-157 | Continuous | 1–10 | 500 mcg | 2x daily | SubQ near injury |
| TB-500 | Loading | 1–4 | 2.5 mg | 2x/week | SubQ (any site) |
| TB-500 | Maintenance | 5–10 | 1.5 mg | 1x/week | SubQ (any site) |
| CJC-1295 (no DAC) | Continuous | 1–10 | 100 mcg | Bedtime | SubQ |
| Ipamorelin | Continuous | 1–10 | 200 mcg | Bedtime | SubQ |
Total duration: 10 weeks Rationale for adding GH secretagogues: BPC-157 enhances GH receptor expression in connective tissue. By elevating GH levels with CJC-1295/Ipamorelin at the same time, you potentially amplify the repair signal that BPC-157's receptor upregulation makes tissue more responsive to.
→ Build any of these protocols with visual timelines in our Protocol Builder — select "Tissue Repair" and your experience level.
→ Verify the Advanced Protocol in our Interaction Checker — all four compounds are rated compatible.
Week-by-Week Dosing Schedule (Intermediate Protocol)
| Day | Week 1–4 | Week 5–8 |
|---|---|---|
| Monday | BPC-157 AM + PM, TB-500 | BPC-157 AM + PM, TB-500 |
| Tuesday | BPC-157 AM + PM | BPC-157 AM + PM |
| Wednesday | BPC-157 AM + PM | BPC-157 AM + PM |
| Thursday | BPC-157 AM + PM, TB-500 | BPC-157 AM + PM |
| Friday | BPC-157 AM + PM | BPC-157 AM + PM |
| Saturday | BPC-157 AM + PM | BPC-157 AM + PM |
| Sunday | BPC-157 AM + PM | BPC-157 AM + PM |
Bolded = TB-500 injection day.
Timing notes:
- BPC-157: Inject roughly 12 hours apart (e.g., 7 AM and 7 PM) for consistent tissue levels
- TB-500: Non-consecutive days during loading. Any time of day — no fasting requirement
- Neither peptide requires an empty stomach (unlike GH secretagogues)
Reconstitution & Preparation
BPC-157 Reconstitution
| Parameter | Value |
|---|---|
| Typical vial | 5 mg |
| Recommended BAC water | 2 mL |
| Resulting concentration | 2.5 mg/mL (2,500 mcg/mL) |
| 500 mcg dose | 20 units on insulin syringe |
| Doses per vial | 10 |
| Vials needed (8-week protocol at 500 mcg 2x/day) | ~11 vials |
TB-500 Reconstitution
| Parameter | Value |
|---|---|
| Typical vial | 5 mg |
| Recommended BAC water | 1 mL |
| Resulting concentration | 5 mg/mL (5,000 mcg/mL) |
| 2.5 mg dose | 50 units on insulin syringe |
| Doses per vial | 2 |
| Vials needed (8-week protocol) | ~6 vials |
Note on TB-500 reconstitution: TB-500 has a higher molecular weight (4,963 Da) and may dissolve more slowly than BPC-157. After adding BAC water, let it sit for 60 seconds, then swirl gently. If particles remain, refrigerate for 30 minutes and try again. Do not shake.
→ Get your exact unit calculations with our Reconstitution Calculator — BPC-157 and TB-500 are both pre-loaded as presets.
→ For step-by-step reconstitution technique, see our Mixing Guide.
Injection Strategy
BPC-157: Inject Locally
BPC-157's angiogenesis mechanism works best locally. Inject as close to the injury as anatomically practical.
For specific injuries:
- Shoulder/rotator cuff: SubQ in the deltoid area near the injury
- Knee (ACL, meniscus, patellar tendon): SubQ on either side of the knee, rotating
- Achilles/ankle: SubQ near the Achilles tendon or ankle joint
- Elbow (tennis/golfer's elbow): SubQ near the affected epicondyle
- Back/spine: SubQ in the lower back or nearest accessible area
- Hip: SubQ over the hip joint area
For systemic/general use: Abdominal SubQ injection, rotating left and right sides.
Do not inject directly into a joint, tendon, or open wound unless specifically directed by a physician. SubQ injections go into the fat layer beneath the skin, not into the tissue itself.
TB-500: Inject Anywhere
TB-500 works systemically — the injection site does not need to be near the injury. Choose any convenient SubQ site: abdomen, outer thigh, or upper arm. Rotate sites between injections.
Why this difference matters: BPC-157's local angiogenesis creates concentrated healing at the injection site. TB-500's cell migration effects are distributed body-wide through the bloodstream. You want BPC-157 targeted and TB-500 convenient.
→ View our interactive Injection Site Map for visual guidance.
What to Expect (Timeline)
Days 1–3: Minimal noticeable effects. The compounds are building tissue concentrations.
Days 4–7: Some users report reduced pain and inflammation at the injury site. Sleep quality may improve slightly. These early effects are subtle — don't expect dramatic changes in the first week.
Weeks 2–3: This is when most users report the first meaningful improvements. Reduced pain during movement, improved range of motion, and decreased swelling are commonly noted. The TB-500 loading phase is building systemic saturation.
Weeks 3–5: The "acceleration window." BPC-157's angiogenesis has had time to establish new blood vessel networks. TB-500 loading is at peak effect. Many users describe this period as when healing "clicks" — noticeable week-over-week improvement.
Weeks 6–8: Continued improvement with the transition to TB-500 maintenance. Some users describe a slight plateau as TB-500 moves from loading to maintenance frequency. BPC-157's consistent daily dosing maintains the repair signal.
Post-protocol (weeks 9+): Structural repairs (healed tendons, ligaments, muscle tissue) tend to persist after discontinuation. The peptides accelerated the repair process; the repaired tissue remains. Some users run a second 8-week cycle after a 4-week break for injuries that need additional healing time.
Important: These timelines are based on anecdotal reports and clinical practice patterns, not controlled clinical trials. Individual responses vary based on injury severity, age, nutrition, sleep quality, and concurrent rehabilitation.
Cost Breakdown
Intermediate Protocol (8 Weeks)
| Item | Quantity | Est. Unit Price | Total |
|---|---|---|---|
| BPC-157 (5 mg vials) | 11 vials | $35 | $385 |
| TB-500 (5 mg vials) | 6 vials | $40 | $240 |
| Bacteriostatic Water (30 mL) | 2 vials | $12 | $24 |
| Insulin Syringes (100-pack) | 2 packs | $15 | $30 |
| Mixing Syringes | 17 | $1 | $17 |
| Alcohol Swabs (200-pack) | 1 pack | $6 | $6 |
| Total | ~$702 |
Cost per week: ~$88 Cost per day: ~$12.50
→ Model this protocol (or customize it) in our Cost Calculator — enter your actual vial prices for precise numbers.
Adding a Third Peptide
The BPC-157 + TB-500 stack is highly effective on its own, but some users add a third compound for specific goals.
+ GHK-Cu (Anti-Aging + Repair)
Adding GHK-Cu brings broad gene expression modulation (4,000+ genes) into the repair stack. Particularly useful when skin quality, scar appearance, or aging-related tissue changes are concurrent concerns. GHK-Cu at 200 mcg/day, SubQ, continuous.
Synergy level: Moderate. Different mechanism adds breadth without redundancy.
+ CJC-1295/Ipamorelin (GH Optimization)
Adding GH secretagogues elevates the hormonal environment for repair. BPC-157's GH receptor upregulation may amplify the effect. CJC-1295 100 mcg + Ipamorelin 200 mcg, combined, at bedtime on empty stomach.
Synergy level: Strong. GH elevation complements tissue repair mechanisms. Adds sleep quality improvement.
+ KPV (Gut + Inflammation)
If gut health or systemic inflammation is a concurrent concern, KPV (500 mcg/day, oral or SubQ) adds targeted anti-inflammatory activity through a pathway distinct from TB-500's. Particularly relevant for athletes with both musculoskeletal injuries and GI issues from NSAID use.
Synergy level: Moderate. Complementary anti-inflammatory mechanisms.
→ Verify any three-peptide combination in our Interaction Checker before starting.
Troubleshooting Common Issues
"I'm not noticing any effects after 2 weeks." Some injuries respond more slowly than others. Chronic or degenerative conditions may take 3–4 weeks for noticeable improvement. Verify your reconstitution math (wrong concentration = wrong dose), ensure vials are stored properly (refrigerated, not frozen), and confirm you're injecting BPC-157 near the injury site, not just in the abdomen.
"The TB-500 takes forever to dissolve." TB-500's larger molecular weight means slower dissolution. After adding BAC water, let it sit for 60 seconds, then swirl gently for 30 seconds. If particles remain, refrigerate for 30 minutes and try again. Slight cloudiness that clears within 2 minutes of swirling is normal during the dissolution process.
"I'm getting bruising at injection sites." Use a fresh needle every time (reused needles dull and cause more tissue trauma). Inject slowly. Avoid visible veins. Apply gentle pressure (don't rub) after withdrawing the needle. Rotating injection sites is essential — never inject the same exact spot twice in a row.
"Should I continue the stack during a deload week?" Yes. Deload weeks (reduced training intensity/volume) are when repair processes can work most efficiently because you're not creating additional tissue damage. Continuing the peptide stack during deloads is generally recommended.
"Can I run a second cycle immediately?" A 2–4 week break between cycles is commonly recommended. This allows you to assess how much healing occurred during the first cycle and prevents potential receptor desensitization from continuous long-term use. Some practitioners run back-to-back cycles for severe injuries under medical supervision.
Frequently Asked Questions
Can I mix BPC-157 and TB-500 in the same syringe? This is not generally recommended. While no published data shows chemical incompatibility, the two peptides have different ideal injection sites (BPC-157 locally, TB-500 systemically). Injecting them separately ensures BPC-157 reaches the target area at full concentration. From a practical standpoint, keeping them in separate syringes is cleaner protocol.
Does the order of injection matter? No. You can inject BPC-157 or TB-500 first — the order has no meaningful impact on efficacy. If injecting both in the same session, simply inject at different sites.
Can I use this stack for post-surgical recovery? Many practitioners use BPC-157 and TB-500 as part of post-surgical recovery protocols. However, consult your surgeon first. Some surgeons have concerns about angiogenesis-promoting compounds immediately post-surgery (related to wound healing dynamics). Timing of peptide initiation relative to surgery should be a clinical decision.
Is this stack effective for chronic injuries (not just acute)? Yes. Many users report improvements in chronic conditions (old tendon injuries, persistent joint issues, degenerative changes) that had not resolved with conventional treatment. Chronic conditions may require longer protocols (10–12 weeks) and potentially multiple cycles. Response rates for chronic injuries are generally slower than acute injuries but still meaningful.
Will I lose my results when I stop the stack? Structural repairs — healed tendon tissue, regenerated blood vessels, repaired muscle fibers — tend to persist after discontinuation. The peptides accelerated a biological repair process; the repaired tissue remains. This is fundamentally different from compounds where the effect is only present while the compound is active (like GH secretagogues' body composition effects).
Related Articles
- BPC-157 vs TB-500: Which Repair Peptide Should You Choose?
- BPC-157: The Complete Research Profile
- TB-500 (Thymosin Beta-4): Full Research Guide
- Best Peptides for Healing Injuries
- How to Reconstitute Peptides: Step-by-Step Guide
Sources
- Gwyer, D., Wragg, N. M., & Wilson, S. L. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 377(2), 153–159. PMID: 31203428
- Seiwerth, S. et al. (2018). BPC 157 and Standard Angiogenic Growth Factors. Current Pharmaceutical Design, 24(18), 1972–1989. PMID: 29756563
- Chang, H. et al. (2014). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules, 19(11). PMID: 25401642
- Kleinman, H. K., & Sosne, G. (2016). Thymosin β4 and the eye: I. Corneal wound healing. Annals of the New York Academy of Sciences, 1374(1). PMID: 27411715
- Sosne, G., Qiu, P., & Goldstein, A. L. (2012). Thymosin beta 4 and the eye. Annals of the New York Academy of Sciences, 1269(1). PMID: 23045976
- Crockatt, M. (2025). IV BPC-157 Safety in Humans at Doses Up to 20mg. Phase I Pilot Study. PMID: 39284103
Medical Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. The peptides discussed are not FDA-approved for tissue repair. Always consult a licensed healthcare professional before beginning any peptide protocol, especially if you are recovering from surgery or have pre-existing conditions.
© 2026 GreyPeptides.com — All rights reserved.
This article is for educational purposes only and does not constitute medical advice. Consult a licensed medical professional before considering any peptide therapy.